Omega-3-Acid, 1 gram recall — The Harvard Drug Group LLC (Class II)

The Harvard Drug Group LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Omega-3-Acid, 1 gram — a Class II recall, initiated 2026-04-09 and posted to the FDA enforcement report on 2026-04-29, under recall number D-0493-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.”. From the product description, the form is capsules, the strengths given are 1 gram and 10 unit, the package is described as 50 capsules and it is marked Rx only. 1 National Drug Code number is printed in the record: 0904-7495-06. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in OH, United States. It is the only recall number the FDA has filed under event ID 98763. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0493-2026
FDA event ID 98763
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm The Harvard Drug Group LLC
Recall initiated 2026-04-09
Reported by FDA 2026-04-29
Report lag 20 days from initiation to report
Distribution Nationwide in the USA — Nationwide (US)
Firm location on record OH, United States
Product description (source) Omega-3-Acid, Ethyl Esters, Capsules, USP, 1 gram, 50 capsules (5 x 10 unit dose blister cards) per carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46288. NDC: 0904-7495-06

Reason reported by FDA

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

19 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 31-word product description above; each is a literal substring of it.

Product named Omega-3-Acid
Form Capsules
Strength 1 gram · 10 unit
Package 50 capsules
NDC 0904-7495-06
Marketing category Rx only
Distributed by Major Pharmaceuticals, Indianapolis

Other indexed recalls from The Harvard Drug Group LLC

2 indexed records name The Harvard Drug Group LLC as the recalling firm, across 2 FDA events, reported 2026-04-29 to 2026-07-01. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
MAJOR, 0.2 mgD-0609-2026Class II0.2 mg · Tablets2026-07-01

Reported in the same month (2026-04)

6 enforcement reports carry a report date in 2026-04; these 4 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Furosemide Tablets, 80 mgD-0486-2026Leading Pharma, LLCClass II2026-04-29
FRESHKOTE LUBRICANT EYEDROPS, 10mLD-0489-2026Harrow Eye LLCClass II2026-04-29
DEXTROSE INJECTION USP, 70%D-0496-2026B Braun Medical IncClass II2026-04-29
LACTATED RINGER'S IRRIGATION, 3000 mLD-0498-2026B Braun Medical IncClass II2026-04-29

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 10 nearest to 2026-04-29 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Systane, 10gD-0491-2026Alcon Research LLC10g · Gel2026-05-06
GenTeal Tears, 10gD-0492-2026Alcon Research LLC10g · Gel2026-05-06
Optase Dry Eye Intense Drops (Glycerin 0.2%)D-0499-2026Scope Health0.2% · Drops2026-05-06
iVIZIA, 0.5%D-0500-2026Thea Pharma, Inc.0.5% · Eye Drops2026-05-06
Similasan, 0.5%D-0501-2026Thea Pharma, Inc.0.5% · Eye Drops2026-05-06
Phenylephrine Hydrochloride Injectable Solution, 40mgD-0502-2026Wells Pharma OF Houston LLC40mg · Solution2026-05-06
fentaNYL Citrate Injectable Solution, 1000 mcg/100 mLD-0503-2026Wells Pharma OF Houston LLC1000 mcg/100 mL · Solution2026-05-06
fentaNYL Citrate injectable Solution in 0.9% Sodium ChlorideD-0504-2026Wells Pharma OF Houston LLC0.9% · Solution2026-05-06
fentaNYL Citrate Injectable Solution, 1250 mcg/25mLD-0505-2026Wells Pharma OF Houston LLC1250 mcg/25mL · Solution2026-05-06
fentaNYL Citrate Injectable Solution in 0.9% Sodium ChlorideD-0506-2026Wells Pharma OF Houston LLC0.9% · Solution2026-05-06

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 0904-7495-06 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); The Harvard Drug Group LLC (2 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0493-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0493-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-04-29
Ingested
2026-08-22
Record hash
e7c943a3812d5f75

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.